Guidant Holds To 2005 Drug-Eluting Stent E.T.A. Despite Trial Delay
This article was originally published in The Gray Sheet
Executive Summary
The start of Guidant's SPIRIT FIRST dose-selection clinical trial for the everolimus-eluting Vision stent will be delayed three to six months due to foreign-body responses detected in pre-clinical studies
You may also be interested in...
DES Utilization Guidelines Give Guidant Comfort; J&J Revisits Cypher Pricing
Guidant is positioning its Multi-Link bare-metal stent platform to benefit from hospital guidelines limiting drug-eluting stent use to FDA-approved indications
DES Utilization Guidelines Give Guidant Comfort; J&J Revisits Cypher Pricing
Guidant is positioning its Multi-Link bare-metal stent platform to benefit from hospital guidelines limiting drug-eluting stent use to FDA-approved indications
Vulnerable Plaques Or Vulnerable Patients? – ACC Debate On Plaque Imaging
Drug-eluting stents could potentially prevent myocardial infarctions by stabilizing vulnerable plaques, according to preclinical research sponsored by Guidant